EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Patient Experience with Linzess (Linaclotide): Efficacy, Discontinuation, and Withdrawal Symptoms

Fareha Rasheed, Muhammad Azhar Jamil, Saira Kanwal, Sibghat Ullah, Bushra Liaquat, Junaid Shah

Journal of Diabesity · 11.09.2025 · 1 (1)

DOI: 10.66381/jod.2025.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Diabesity, online erschienen am 11.09.2025. Verfasst von Fareha Rasheed und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Linaclotide (Linzess) is a guanylate cyclase-C agonist used for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). While clinical trials support its effectiveness and safety, real-world data from patients remain essential for understanding long-term outcomes, discontinuation causes, and withdrawal experiences.

Objective

To assess the effectiveness of Linaclotide use, reasons for discontinuation, and post-discontinuation symptoms through a patient-reported survey.

Methods

An online survey (social media) was conducted with 86 respondents who had used linaclotide. Questions focused on duration of use, reason for prescription, symptom improvement, causes of discontinuation, and post-discontinuation gastrointestinal and systemic symptoms.

Results

Among 86 respondents, 48% used linaclotide for less than three months and 37% for more than six months. The primary indication was constipation (71%) followed by irritable bowel syndrome (29%). Complete symptom resolution was reported by 35% of patients, while 47% had partial improvement and 18% reported no benefit. Discontinuation was common, with 49% stopping due to side effects and 29% due to cost or insurance issues. After discontinuation, abdominal pain (46%) and constipation (34%) were the most frequent gastrointestinal symptoms, whereas systemic withdrawal-like symptoms included headache (24%), anxiety or depression (24%), fatigue (20%), and sweating (12%).

Conclusion

While many patients experience some benefit from linaclotide, side effects, affordability, and symptom recurrence after discontinuation remain challenges. Post-discontinuation withdrawal-like symptoms may occur and warrant clinical recognition and management. Keywords: Linaclotide; constipation; IBS-C; side effects; Linzess

Zitieren

APA

Rasheed, F., Jamil, M. A., Kanwal, S., Ullah, S., Liaquat, B., & Shah, J. (2025). Real-World Patient Experience with Linzess (Linaclotide): Efficacy, Discontinuation, and Withdrawal Symptoms. Journal of Diabesity, 1(1). https://doi.org/10.66381/jod.2025.002

Vancouver

Rasheed F, Jamil MA, Kanwal S, Ullah S, Liaquat B, Shah J. Real-World Patient Experience with Linzess (Linaclotide): Efficacy, Discontinuation, and Withdrawal Symptoms. Journal of Diabesity. 2025;1(1). doi:10.66381/jod.2025.002

BibTeX
@article{Rasheed2025,
  author = {Rasheed, Fareha and Jamil, Muhammad Azhar and Kanwal, Saira and Ullah, Sibghat and Liaquat, Bushra and Shah, Junaid},
  title = {Real-World Patient Experience with Linzess (Linaclotide): Efficacy, Discontinuation, and Withdrawal Symptoms},
  journal = {Journal of Diabesity},
  year = {2025},
  volume = {1},
  number = {1},
  doi = {10.66381/jod.2025.002}
}
Kostenlos starten →